Core Viewpoint - Picard Medical, Inc. will showcase its SynCardia Total Artificial Heart (STAH) at the American Heart Association (AHA) annual meeting, highlighting its status as the most widely used and studied artificial heart globally [1][5]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona. It is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [5]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [5]. - Over 2,100 implants of the STAH have been performed in hospitals across 27 countries, establishing it as the most widely used and extensively studied artificial heart in the world [5]. Event Participation - The AHA annual meeting will take place from November 7 to 10 in New Orleans, Louisiana, where Picard Medical will exhibit at booth 3408 [1]. - The CEO of Picard Medical expressed excitement about sharing the latest developments regarding the STAH and engaging with physicians and attendees about patient eligibility and clinical data [2]. AHA Overview - The American Heart Association (AHA) is the oldest and largest voluntary organization in the U.S. dedicated to combating heart disease and stroke, with over 35 million volunteers and supporters [4]. - The AHA has invested more than $6 billion in cardiovascular research, making it the largest non-profit funding source for cardiovascular and cerebrovascular disease research after the federal government [4].

Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early ...